University of California San Francisco

Norah Terrault - 144
Norah
Terrault
MD, MPH

Professor of Clinical Medicine & Surgery
Departments of Medicine & Surgery
Director of Viral Hepatitis Research in Liver Transplantation

Address

513 Parnassus Avenue, MSB, #357
San Francisco, CA 94143
United States

Email: [email protected]
Phone: 415-476-2227
Fax: 415-476-0659

    Biography

    Dr. Norah Terrault is a hepatologist or liver specialist who is recognized internationally for the treatment of viral hepatitis and liver transplantation. Her research includes the study of viral hepatitis and its progression and treatment, especially in liver transplant patients. Her research includes several clinical trials related to preventing and treating chronic hepatitis C and B. Her studies in this area have been presented to the American Association for the Study of Liver Diseases, the leading organization for research in liver disease.

    Terrault completed medical training at the University of Alberta and specialty medical training in Internal Medicine and Gastroenterology at the University of Toronto, both in Canada. Her post-doctoral fellowship in hepatology and viral hepatitis was completed at the University of California, San Francisco while earning a concurrent master's degree in public health from the University of California at Berkeley. She joined the medical staff at UCSF Medical Center in 1997.

    Education

    Institution Degree Dept or School End Date
    University of California, San Francisco Post-Doc Fellow/Scholar Medicine 1995
    University of Alberta M.D. School of Medicine 1987
    University of California, San Francisco Residency
    University of California, San Francisco Clinical Fellowship Gastroenterology

    Board Certifications

    American Board of Internal Medicine, Internal Medicine

    American Board of Internal Medicine, Gastroenterology

    Clinical Expertise

    Alcoholic Liver Disease
    Autoimmune Hepatitis
    Benign Liver Tumors
    Cirrhosis
    Fulminant Hepatic Failure
    Hepatitis B
    Hepatitis C
    Hepatocellular Carcinoma (Liver Cancer)
    Live Donor Liver Transplantation
    Liver Transplantation
    Nonalcoholic Fatty Liver Disease
    Pancreas Transplantation
    Primary Biliary Cirrhosis
    Primary Sclerosing Cholangitis

    Clinical Trials

    1. Related Conditions: Hepatitis C, Viruses, Hepatocellular Cancer, Liver Cancer, Hepatitis, Cirrhosis, Liver Transplant, Hepatitis A| Start Date: | End Date:
    2. Related Conditions: Hepatitis B, Liver Disease, Liver Transplant, Hepatitis A, Hepatitis| Start Date: | End Date:

    Program Affiliations

    UCSF Liver Center

    In the News

    December, 20, 2014 | UCSF Transplant Surgery

    Grants and Funding

    • USC Cirrhosis Clinical Center | NIH | 2021-09-22 - 2026-08-31 | Role: Principal Investigator
    • Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) | NIH | 2002-06-15 - 2024-06-30 | Role: Principal Investigator
    • Hepatitis B Research Network (HBRN): Natural History and Treatment Studies | NIH | 2008-09-30 - 2021-05-31 | Role: Principal Investigator
    • Bay Area Hepatitis C Cooperative Research Center | NIH | 2010-06-15 - 2016-05-31 | Role: Co-Investigator
    • General Clinical Research Center | NIH | 1974-12-01 - 2009-03-31 | Role: Co-Investigator
    • Resistance to Antiviral Therapy in Chronic Hepatitis C | NIH | 2001-08-01 - 2007-04-30 | Role: Principal Investigator

    Research Narrative

    My research focuses on the natural history and treatment of hepatitis C virus (HCV) and hepatitis B virus (HBV), particularly in special populations, including those undergoing liver transplantation. Work in progress addresses the natural history of post-transplant disease and specific therapies to prevent infection or modify HCV and HBV disease progression and loss of grafts from recurrent disease.

    Our virological analyses are focused on characterization of viral mutations that occur in liver transplant recipients receiving antiviral therapies and assessment of the effect of these variant viruses on the natural history and severity of disease post-transplantation. Knowledge of these factors may allow improved organ allocation by identifying subsets of patients with HCV recurrence in liver grafts who would be favorable or unfavorable candidates for retransplantation. 

    Research Interests

    Liver Injury and Repair

    Hepatitis B virus (HBV)

    Hepatitis C virus (HCV)

    Publications

    MOST RECENT PUBLICATIONS FROM A TOTAL OF 414
    1. Reply: Recognizing the new nomenclature requires a comprehensive analysis of the prevalence, severity, and long-term outlook for SLD and subclassifications.
      Lee BP, Dodge JL, Terrault NA| | PubMed
    2. Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET study.
      Aleyadeh W, Verna EC, Elbeshbeshy H, Sulkowski MS, Smith C, Darling J, Sterling RK, Muir A, Akushevich L, La D, Terrault N, Fried MW, Feld JJ| | PubMed
    3. Hepatitis C.
      Martinello M, Solomon SS, Terrault NA, Dore GJ| | PubMed
    4. National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
      Lee BP, Dodge JL, Terrault NA| | PubMed
    5. Antimullerian Hormone, a Marker of Ovarian Reserve, Is Protective Against Presence and Severity of NASH in Premenopausal Women.
      Maldonado SS, Cedars MI, Yates KP, Wilson LA, Gill R, Terrault NA, Suzuki A, Sarkar MA| | PubMed
    6. Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with "Ludwig disease".
      Newsome P, Rinella ME, Lazarus JV, Terrault N| | PubMed
    7. HDV RNA assays: Performance characteristics, clinical utility, and challenges.
      Wedemeyer H, Leus M, Battersby TR, Glenn J, Gordien E, Kamili S, Kapoor H, Kessler HH, Lenz O, LĂĽtgehetmann M, Mixson-Hayden T, Simon CO, Thomson M, Westman G, Miller V, Terrault N, Lampertico P, HDV RNA Assays Writing Group at the HBV Forum| | PubMed
    8. A global action agenda for turning the tide on fatty liver disease.
      Lazarus JV, Mark HE, Allen AM, Arab JP, Carrieri P, Noureddin M, Alazawi W, Alkhouri N, Alqahtani SA, Anstee QM, Arrese M, Bataller R, Berg T, Brennan PN, Burra P, Castro-Narro GE, Cortez-Pinto H, Cusi K, Dedes N, Duseja A, Francque SM, Gastaldelli A, Hagström H, Huang TTK, Ivancovsky Wajcman D, Kautz A, Kopka CJ, Krag A, Newsome PN, Rinella ME, Romero D, Sarin SK, Silva M, Spearman CW, Terrault NA, Tsochatzis EA, Valenti L, Villota-Rivas M, Zelber-Sagi S, Schattenberg JM, Wong VW, Younossi ZM, Healthy Livers, Healthy Lives Collaborators| | PubMed
    9. Association of nativity with survival among adults with hepatocellular carcinoma.
      Zhou K, Song Z, Rostomian N, Dodge JL, Stern MC, Setiawan VW, Terrault NA, Cockburn MG, Liu L| | PubMed
    10. Global importance of new treatment strategies to efforts to control hepatitis B virus.
      Forbes C, Lavoie L, Satram S, Shen L, Thanawala V, Arizpe A, Terrault N| | PubMed